Anatara Lifesciences Ltd · ASX:ANR
Anatara Lifesciences — Shareholder Meeting (November 2020)
19 slides from Anatara Lifesciences's shareholder meeting presentation, Nov 26, 2020
Slide 1: Advancing gastrointestinal health – AGM November 2020
For personal use only Advancing gastrointestinal health AGM NOVEMBER 2020 ------------------------ ASX: ANR
Slide 2: Disclaimer
Disclaimer For personal use only The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Anatara Lifesciences Ltd, ACN
Slide 3: Key Investor Message
Key Investor Message For personal use only More than ever, the world is looking for safe and effective solutions to gut health. The Anatara team is focussed on delivering evidence-based, commercially attractive solutions for gastrointestinal diseases in animals and humans. 3
Slide 4: Corporate Fast Facts
Corporate Fast Facts Board of Directors: For personal use only Sue MacLeman ASX ticker code Dr Jane Ryan ANR Dr Tracie Ramsdale Dr David Brookes Management: Steve Lydeamore, CEO Dr Michael West, COO Share Price Market Capitalisation Product Development $0.175* $11.7 million* Advisory Board: Prof Pet
Slide 5: Achievements
Achievements For personal use only Human health asset, GaRP: • Intellectual property strengthened • Achieved preclinical milestone • Achieved clinical trial protocol milestone • Clinical trial protocol modified to a ‘virtual’ clinical trial in IBS • GMP manufacturing process completed allowing clini
Slide 6: Our place in the microbiome treatment landscape
Our place in the microbiome treatment landscape Identifying a specific bacterial Drugs that specifically target the Fecal microbiota treatment (FMT) For personal use only strain, or group of strains, that is bacteria that cause disease while delivered alive to the patient’s leaving the rest of the g
Slide 7: Irritable Bowel Syndrome
For personal use only Irritable Bowel Syndrome
Slide 8: IBS – Patient Impact
IBS is the most commonly diagnosed IBS – Patient Impact gastrointestinal condition and a significant cost burden on health care 2. For personal use only Worldwide prevalence of IBS 1 45% of IBS-D patients agreed 11.2% with the statement “I’m willing to try anything to help manage my IBS”10 14% Indiv
Slide 9: Attractive Target Market
Attractive Target Market Unmet need: limited For personal use only pharmacological treatment options; symptoms not well controlled6 60% demand for Prevalence: 11.2% of complementary global population5 and alternative medicines (CAM)6 Gastrointestinal IBS supplements and OTC Recommended by digestive
Slide 10: Compelling Solution
Compelling Solution For personal use only Intellectual Property Parallel licensing Strong pre-clinical discussions with global consumer data to support use health companies in IBS GaRP Product delivered to Clinical trial in IBS where action is planned for late 2020 needed – the ‘gut’ GMP manufacturi
Slide 11: Global consumer health market opportunity
Global consumer health market opportunity For personal use only Gastrointestinal supplements and OTC US $8 billion digestive remedies in USA alone 3,4 Probiotic supplements Other GI supplements OTC digestive supplements Align® (P&G) sales Iberogast® (Bayer) sales Buscopan® (Sanofi) sales (U.S.) 2018
Slide 12: GaRP built on strong scientific foundations
For personal use only GaRP built on strong scientific foundations 12
Slide 13: Anatara's Unique Complementary Medicine - How does it work?
Anatara’s Unique Complementary Small Intestine Medicine - How does it work? For personal use only Small Intestine Colon Colon Correcting Alleviation of gut microbiota the Repair of gut to restore Reduction of symptomatic lining and normal inflammation diarrhoea barrier defects microbial associated w
Slide 14: GaRP has been shown to…
GaRP has been shown to….. • Address the dysbiosis of the microbiome For personal use only • Inhibiting the attachment and invasion of pro-inflammatory bacteria by >95% • Reduce gut inflammation • Reducing the production of pro-inflammatory proteins by >85% • Reducing colon inflammation and disrupted
Slide 15: Grounded in scientific evidence
Grounded in scientific evidence For personal use only Successful Proof of Concept Studies (February & October 2019) Demonstrated using industry-standard in vitro gut models 15
Slide 16: Next step: clinical trial
Next step: clinical trial Description: An adaptive, Randomized, Double-blinded, Placebo-controlled virtual clinical trial For personal use only Population: Males and females 18-65 years of age with irritable bowel syndrome (IBS-SSS score of 175-300 and categorised as IBS-diarrhoea subtype on ROME IV
Slide 17: Future opportunities
Future opportunities Anatara has the potential to leverage and For personal use only apply the proprietary know-how and IP created through the development of our GaRP complementary medicine into other gastrointestinal diseases that are caused by a disrupted microbiome, inflammation and mucosal damag
Slide 18: Anticipated Company Milestones
Anticipated Company Milestones 2018 2018 2019 2019 2020 2020 2021 2021 For personal use only H1 H2 H1 H2 H1 H2 H1 H2 GaRP commercial feasibility Patent Application filed In vitro GaRP proof of concept - anti-inflammation - anti-attachment In vitro GaRP proof of concept - mucosal healing Ga
Slide 19: Contact Anatara Lifesciences Ltd
For personal use only Contact Anatara Lifesciences Ltd Steven Lydeamore, Chief Executive Officer +61 438 027 172 slydeamore@anatara.com www.anataralifesciences.com @AnataraANR anatara-lifesciences-ltd
Anatara Lifesciences — Shareholder Meeting (November 2020) on 6ix